RELIEF THERAPEUTICS Holding SA logo

RLF - RELIEF THERAPEUTICS Holding SA Share Price

CHF0.502 -0.0  -1.2%

Last Trade - 18/09/20

Market Cap £1.09bn
Enterprise Value £1.09bn
Revenue £n/a
Position in Universe 349th / 1039
Bullish
Bearish
Unlock RLF Revenue
Momentum
Relative Strength (%)
1m -3.09%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -36.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.015 0.000 0.57 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, RELIEF THERAPEUTICS Holding SA revenues was not reported. Net income totaled SF8.3M vs. loss of SF556K. Net income reflects Finance income increase from SF14K to SF35K (income), personnel expense decrease of 3% to SF200K (expense), Depreciation and amortisation expense decrease from SF1K (expense) to SF0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RLF Revenue Unlock RLF Revenue

Net Income

RLF Net Income Unlock RLF Revenue

Normalised EPS

RLF Normalised EPS Unlock RLF Revenue

PE Ratio Range

RLF PE Ratio Range Unlock RLF Revenue

Dividend Yield Range

RLF Dividend Yield Range Unlock RLF Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RLF EPS Forecasts Unlock RLF Revenue
Profile Summary

RELIEF THERAPEUTICS Holding SA, formerly known as mondoBIOTECH holding AG, is a Switzerland-based company that focuses on the development of treatments of diabetic complications and respiratory diseases. It specializes in clinical stage project and drugs of natural human origin (peptides and proteins) with a history of clinical testing and use in human patients. Its main products are Aviptadil and Atexakin Alfa. Aviptadil is an abundant biologically active endogenous human peptide acting as a ligand on specific G-protein coupled transmembrane receptors. Atexakin Alfa is a low-dosage formulation of interleukin-6 (IL-6), a cytokine that promotes nerve regeneration and remyelination, and protects neurons from toxic injuries.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated March 20, 2007
Public Since September 19, 2011
No. of Shareholders: n/a
No. of Employees: 24
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange SIX Swiss Exchange
Shares in Issue 2,534,668,581
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RLF Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RLF
Upcoming Events for RLF
Frequently Asked Questions for RELIEF THERAPEUTICS Holding SA
What is the RELIEF THERAPEUTICS Holding SA share price?

As of 18/09/20, shares in RELIEF THERAPEUTICS Holding SA are trading at CHF0.502, giving the company a market capitalisation of £1.09bn. This share price information is delayed by 15 minutes.

How has the RELIEF THERAPEUTICS Holding SA share price performed this year?

Shares in RELIEF THERAPEUTICS Holding SA are currently trading at CHF0.502 and the price has moved by 36.2k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the RELIEF THERAPEUTICS Holding SA price has moved by 38.5k% over the past year.

What are the analyst and broker recommendations for RELIEF THERAPEUTICS Holding SA?

Of the analysts with advisory recommendations for RELIEF THERAPEUTICS Holding SA, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for RELIEF THERAPEUTICS Holding SA is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will RELIEF THERAPEUTICS Holding SA next release its financial results?

RELIEF THERAPEUTICS Holding SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the RELIEF THERAPEUTICS Holding SA dividend yield?

RELIEF THERAPEUTICS Holding SA does not currently pay a dividend.

Does RELIEF THERAPEUTICS Holding SA pay a dividend?

RELIEF THERAPEUTICS Holding SA does not currently pay a dividend.

When does RELIEF THERAPEUTICS Holding SA next pay dividends?

RELIEF THERAPEUTICS Holding SA does not currently pay a dividend.

How do I buy RELIEF THERAPEUTICS Holding SA shares?

To buy shares in RELIEF THERAPEUTICS Holding SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of RELIEF THERAPEUTICS Holding SA?

Shares in RELIEF THERAPEUTICS Holding SA are currently trading at CHF0.502, giving the company a market capitalisation of £1.09bn.

Where are RELIEF THERAPEUTICS Holding SA shares listed? Where are RELIEF THERAPEUTICS Holding SA shares listed?

Here are the trading details for RELIEF THERAPEUTICS Holding SA:

Country of listing: Switzerland
Exchange: SWX
Ticker Symbol: RLF
What kind of share is RELIEF THERAPEUTICS Holding SA?

Based on an overall assessment of its quality, value and momentum, RELIEF THERAPEUTICS Holding SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a RELIEF THERAPEUTICS Holding SA share price forecast 2020?

We were not able to load any forecast data for RELIEF THERAPEUTICS Holding SA.

How can I tell whether the RELIEF THERAPEUTICS Holding SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RELIEF THERAPEUTICS Holding SA. Over the past six months, the relative strength of its shares against the market has been 2.93k%. At the current price of CHF0.502, shares in RELIEF THERAPEUTICS Holding SA are trading at 0.450k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the RELIEF THERAPEUTICS Holding SA PE Ratio?

The RELIEF THERAPEUTICS Holding SA PE ratio based on its reported earnings over the past 12 months is 2.82k. The shares are currently trading at CHF0.502.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of RELIEF THERAPEUTICS Holding SA?

RELIEF THERAPEUTICS Holding SA's management team is headed by:

Dorian Bevec - EXO
Raghuram Selvaraju - CHM
Peter de Svastich - DRC
Thomaz Burkhardt - DRC
Gilles Della Corte - OTH
Who are the major shareholders of RELIEF THERAPEUTICS Holding SA?

Here are the top five shareholders of RELIEF THERAPEUTICS Holding SA based on the size of their shareholding:

Global Emerging Markets Private Equity
Percentage owned: 27.91% (707.5m shares)
Hedou (Gael) Individual Investor
Percentage owned: 4.16% (105.5m shares)
Sagot (Yves) Individual Investor
Percentage owned: 3.69% (93.6m shares)
HERCULIS Partners Aries Fund Hedge Fund Portfolio
Percentage owned: 1.3% (33.0m shares)
Herculis Partners SA Investment Advisor
Percentage owned: 1.3% (33.0m shares)
Similar to RLF
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.